|
| 碳离子放射治疗胰腺癌的临床疗效、安全性及预后因素分析 |
| Carbon-Ion Radiotherapy for Pancreatic Cancer: Clinical Efficacy, Safety, and Prognostic Factors |
| 投稿时间：2025-11-29 修订日期：2025-12-15 |
| DOI： |
|
 |
| 中文关键词: 胰腺癌 碳离子放射治疗 安全性 预后 |
| 英文关键词:pancreatic cancer carbon-ion radiotherapy safety prognosis |
| 基金项目:甘肃省自然科学基金（项目编号：23JRRH0006）；陇原青年创新创业人才基金（项目编号：2021LQTD14）；甘肃中医药大学研究生创新基金 |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| [目的] 探讨碳离子放疗（Carbon Ion Radiotherapy, CIRT）治疗胰腺癌的临床疗效、安全性及影响患者生存的预后因素。[方法] 回顾性分析2020年1月至2025年8月期间在本中心完成CIRT的44例胰腺癌患者的临床资料。部分患者接受了CIRT联合化疗、靶向或免疫治疗。研究主要终点为总生存期（Overall Survival, OS），次要终点为急性毒性反应。采用Kaplan-Meier法计算生存率并绘制生存曲线，使用Log-rank检验进行单因素分析。[结果] 全组患者随访时间为 5~53个月，中位生存期（median Overall Survival, mOS）为16个月（95% CI：14.59~NA）。治疗后1年、2年及3年累计生存率分别为71.06%、38.92%和25.94%。全组患者均顺利完成治疗，未发生3级及以上急性不良反应，仅3例出现1~2级放射性十二指肠炎。单因素分析显示：性别、日常生活能力评分（Activities of Daily Living, ADL）、治疗前CA19-9水平及中性粒细胞与淋巴细胞比值（Neutrophil-to-Lymphocyte Ratio, NLR）是影响OS的显著预后因素（P < 0.05）。[结论] CIRT具有良好的耐受性和安全性，即使在较高剂量下亦未增加严重不良反应，并为胰腺癌患者带来较好的生存获益。 |
| 英文摘要: |
| [Objective:] To investigate the clinical efficacy, safety, and prognostic factors affecting survival in pancreatic cancer patients treated with carbon ion radiotherapy (CIRT). [Methods] Clinical data of 44 pancreatic cancer patients who completed CIRT at our center from January 2020 to August 2025 were retrospectively analyzed. Some patients also received CIRT combined with chemotherapy, targeted therapy, or immunotherapy. The primary endpoint was overall survival (OS), and the secondary endpoint was acute toxicity. Survival rates were calculated using the Kaplan–Meier method, and survival curves were plotted. Univariate analysis was performed using the log-rank test. [Results] The follow-up period ranged from 5 to 53 months. The median overall survival (mOS) was 16 months (95% CI: 14.59–NA). The 1-, 2-, and 3-year OS rates were 71.06%, 38.92%, and 25.94%, respectively. All patients completed the treatment successfully, with no grade ≥3 acute adverse events. Only 3 patients experienced grade 1~2 radiation-induced duodenitis. Univariate analysis showed that sex, Activities of Daily Living (ADL) score, pre-treatment CA19-9 level, and neutrophil-to-lymphocyte ratio (NLR) were significant prognostic factors for OS (P < 0.05). [Conclusion] CIRT is well tolerated and safe, even at relatively high doses, without increasing severe adverse events, and provides favorable survival benefits for pancreatic cancer patients. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|